Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients Authors: Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato Published: 2026 ABSTRACT ABSTRACTPOLASTAR (jRCT1071220082) is a multicenter, prospective observational study evaluating the real‐world efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola‐R‐CHP) in Japanese patients with diffuse large B‐cell lymphoma (DLBCL), addressing the limited real‐world data in this setting. Patients ≥ 18 years, with previously untreated DLBCL, receiving Pola‐R‐CHP were enrolled. Patients excluded from POLARIX (NCT03274492), including those > 80 years, were included. Overall, 485 patients were included in the full analysis set (FAS; median age, 71 years [range 27–93]; age ≤ 80 years, 87.6%; International Prognostic Index score 2–5, 73.7%). Median relative dose intensity (RDI) for rituximab and polatuzumab vedotin was ≥ 93.0% (both FAS and patients > 80 years), and for the chemotherapy components median RDI was ≥ 87.2% in the FAS and ≥ 49.6% for patients > 80 years. Grade ≥ 3 adverse events (AEs) occurred in 47.4% of patients in the FAS and 56.7% of patients > 80 years; serious AEs occurred in 12.6% and 25.0%, respectively. The most common Grade ≥ 3 AE (FAS/> 80 years) was neutrophil count decreased (25.6%/26.7%). In the FAS, 5 (1.0%) deaths due to AEs were reported and 33 (6.8%) patients discontinued polatuzumab vedotin due to AEs. No new safety signals were observed. In the FAS, overall response rate and complete response rate (95% confidence interval [CI]) were 93.2% (90.5–95.2) and 83.3% (79.6–86.5), respectively, and were 87.3% (76.0–93.7) and 80.0% (67.6–88.4) in patients > 80 years. Safety and efficacy of Pola‐R‐CHP in Japanese patients, including those > 80 years, were consistent with results from POLARIX. Trial Registration: Japan Registry of Clinical Trials (jRCT1071220082) Abbreviations activated B‐cell adverse events confidence interval cell of origin complete response rate computed tomography diffuse large B‐cell lymphoma end‐of‐treatment full analysis set geriatric 8 germinal center B‐cell International Prognostic Index overall response rate progression‐free survival peripheral neuropathy polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisolone relative dose intensity Introduction Frontline immunochemotherapy comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R‐CHOP) offers a potential cure for approximately 60% of patients with previously untreated diffuse large B‐cell lymphoma (DLBCL); however, approximately 40% of patients do not respond or relapse following initial treatment, creating an unmet need for effective therapies [1]. Efforts to improve on the efficacy of R‐CHOP over the last two decades, including intensification of chemotherapy or addition of novel drugs, have had limited success, and until recently R‐CHOP remained the standard of care for previously untreated DLBCL [1]. Polatuzumab vedotin, an antibody drug conjugate, is composed of a humanized anti‐CD79b monoclonal antibody, conjugated with a protease‐cleavable linker to the potent microtubule inhibitor monomethyl auristatin E [2, 3]. Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisolone (Pola‐R‐CHP) is approved for the treatment of patients with previously untreated DLBCL in more than 100 countries, including Japan as of August 2022 [4], where it is reimbursed under the national health insurance system. This approval was based on the Phase III POLARIX study (NCT03274492), which demonstrated a statistically significant improvement in progression‐free survival (PFS) with Pola‐R‐CHP versus R‐CHOP, with comparable safety, in patients with previously untreated DLBCL [5]. In the current Japanese Practical Guidelines for Hematological Malignancies, Pola‐R‐CHP is recommended for previously untreated patients with DLBCL aged 18–80 years with an International Prognostic Index (IPI) score of ≥ 2 [6, 7]. Pola‐R‐CHP demonstrated consistent efficacy and safety versus R‐CHOP in the Asia subpopulation analysis of POLARIX, which included 281 patients from China, Japan, Korea, and Taiwan [8]. However, of the 85 Japanese patients enrolled, only 44 received Pola‐R‐CHP limiting the application of the findings to real‐world use of Pola‐R‐CHP in Japan. Through the inclusion of a larger and more diverse patient population, encompassing patients ineligible for POLARIX (e.g., those > 80 years), real‐world studies of Pola‐R‐CHP as first‐line therapy in DLBCL will help address the limitations of clinical trial data. In addition, real‐world studies can facilitate exploration of better biomarker candidates (e.g., circulating tumor DNA), and provide valuable insights into post‐marketing safety. The real‐world observational POLASTAR study was designed to investigate the safety and efficacy of Pola‐R‐CHP for patients with previously untreated DLBCL in a clinical setting in Japan. Results from a pre‐specified preliminary analysis of the first 200 patients treated with Pola‐R‐CHP in POLASTAR have been previously reported [9]. Pola‐R‐CHP in Japanese patients demonstrated efficacy and safety data consistent with POLARIX, suggesting that Pola‐R‐CHP may be effective and safe for patients with previously untreated DLBCL in the real‐world population, including elderly patients with appropriate monitoring and dose adjustments [9, 10]. Here, we report a pre‐specified interim analysis of safety and response rates at end of treatment (EOT) for 500 patients in Japan with previously untreated DLBCL treated with Pola‐R‐CHP. Methods Study Design and Patients POLASTAR (jRCT1071220082) is a nationwide, multicenter, prospective, real‐world observational study assessing the efficacy and safety of Pola‐R‐CHP in patients with previously untreated DLBCL. Eligible patients aged ≥ 18 years received Pola‐R‐CHP according to the latest package insert as part of their routine clinical care, based on the Japanese Clinical Guideline [6]. Patients were included based on physician's choice, with no restrictions on age, IPI score, or Eastern Cooperative Oncology Group performance status (ECOG PS). All patients provided written informed consent. The planned observation period was 3 years from the date of administration of the first Pola‐R‐CHP dose for the last enrolled patient. Data were obtained from medical records and clinical diagnosis was carried out at each site; central review for diagnosis was not performed. Biological samples were collected during routine care with no restrictions on the use or extent of tests, medications, or other medical acts performed for diagnostic or therapeutic purposes. Cell of origin (COO) and genetic subtypes, assessed by gene expression and genomic profiling, respectively, were assessed centrally (Riken Genesis Laboratory) using baseline tissue specimens. Investigators were required to refer to the latest package insert when providing treatment. There were no guidelines on: dosing schedule; criteria for dose reduction, interruption, or discontinuation; drugs to be used for treatment; or supportive care to be provided during treatment. Initial dose reductions were permitted based on the physician's decision. Endpoints and Outcome Assessments The primary endpoint was overall survival (not reported in this analysis). Secondary endpoints reported here include safety, and investigator‐assessed overall response rate (ORR) and complete response rate (CRR) at EOT. ORR and CRR at EOT were based on the first evaluation after completion or discontinuation of treatment using the Lugano Classification of response assessment for lymphoma [11]. The method for assessment of response was determined by the treating physician; positron emission tomography (PET) or computed tomography (CT) were not mandatory. Patients included in the efficacy‐evaluable population had a response evaluation as well as data at completion or discontinuation of treatment and baseline data. Grade ≥ 3 adverse events (AEs), and AEs leading to polatuzumab vedotin discontinuation, regardless of grade, were collected. The severity of AEs was determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [12]. The safety evaluation period for AEs was defined as the start of treatment until 90 days after the discontinuation or completion of planned Pola‐R‐CHP treatment or until the start of subsequent therapy, whichever occurred first. Safety and efficacy in the context of demographic/baseline characteristics as well as geriatric functional assessment, assessed using the Geriatric 8 (G8) survey in patients ≥ 65 years, were investigated (G8 score range 0 [heavily impaired–frail] to 17 [no impairment–non‐frail]; cut‐off ≤ 14 points indicative of frailty) [13]. Relative dose intensity (RDI) was also calculated (Supplementary Methods). Statistical Analysis A target sample size of 500 patients was set based on feasibility (without a predetermined hypothesis), which enabled precise estimation of the 2‐year survival rate in a patient population reflecting the real‐world clinical environment in Japan. Among the 500 patients, 125 patients were estimated to relapse and receive second‐line therapy within 2 years. A 2‐year survival rate of approximately 85% based on POLARIX and no censoring at timepoints up to 2 years was assumed with a 95% confidence interval (CI) estimation of 81.8%–88.1%. Among the 500 patients, 60 patients > 80 years were estimated for enrollment. Based on a previous study [14], assuming a 2‐year survival rate of 60% in this population, the 95% CI was estimated as 47.6%–72.4%. CIs for ORR and CRR were calculated using Wilson's method. Continuous data are presented using summary statistics, including arithmetic and geometric means, median, range, and standard deviations. Categorical data are presented using summary statistics, such as frequency and contingency tables. Results Patients Overall, 502 patients were prospectively enrolled across 71 sites between February 9 and December 6, 2023. The clinical cut‐off date for this pre‐specified interim analysis was August 31, 2024. In total, 485 patients were included in the full analysis set (FAS) and 484/485 (99.8%) patients completed the safety evaluation period. Reasons for exclusion from the FAS included initiation of steroids for Pola‐R‐CHP treatment prior to enrollment (n = 6), Pola‐R‐CHP treatment started before enrollment (n = 4), study discontinuation (n = 4), withdrawal of consent (n = 2), and duplicated registration (n = 1). Baseline demographic and clinical characteristics in the FAS, and in patients ≤ 80 and > 80 years, are summarized in Table 1; corresponding data for patients with low (0/1) versus high (2–5) IPI are shown in Table S1. In the FAS, median age was 71.0 years (range 27–93) and 60 (12.4%) patients were > 80 years (Table 1). A total of 351/476 (73.7%) patients had an IPI of 2–5 and 451/476 (94.7%) patients had an ECOG PS of 0–2; ECOG PS was not reported in 9 patients due to missing data, and IPI was also not reported for these patients. TABLE 1Baseline demographic and clinical characteristics in the FAS. n (%), unless otherwise statedFAS (N = 485)≤ 80 years (n = 425)> 80 years (n = 60)Median age (range), years71 (27–93)70 (27–80)84 (81–93)SexMale271 (55.9)231 (54.4)40 (66.7)Clinical diagnosisDLBCL468 (96.5)410 (96.5)58 (96.7)EBV‐positive DLBCL, NOS6 (1.2)4 (0.9)2 (3.3)Intravascular large B‐cell lymphoma4 (0.8)4 (0.9)0 (0.0)Grade 3b follicular lymphoma3 (0.6)3 (0.6)0 (0.0)Other4 (0.8) a 4 (0.9) a 0 (0.0)Transformed low‐grade lymphoma17 (3.5)16 (3.8)1 (1.7)ECOG performance status n = 476 n = 417 n = 590–2451 (94.7)399 (95.7)52 (88.1)3–425 (5.3)18 (4.3)7 (11.9)Ann Arbor stageI60 (12.4)54 (12.7)6 (10.0)II128 (26.4)108 (25.4)20 (33.3)III85 (17.5)74 (17.4)11 (18.3)IV212 (43.7)189 (44.5)23 (38.3)IPI n = 4760/1125 (26.3)119 (28.5)6 (10.2)2–5351 (73.7)298 (71.5)53 (89.8)G8 n = 330 n = 273 n = 57≤ 14243 (73.6)191 (70.0)52 (91.2)> 1487 (26.4)82 (30.0)5 (8.8)Bulky disease (≥ 7.5 cm)80 (16.5)72 (16.9)8 (13.3)Median time from initial diagnosis (defined as date of biopsy) to treatment initiation, (range) days26.0 (4.0–428.0)26.0 (4.0–428.0)23.5 (9.0–211.0)LDH level≤ ULN212 (43.7)195 (45.9)17 (28.3)Involved extranodal sites0/1337 (69.5)295 (69.4)42 (70.0)≥ 2148 (30.5)130 (30.6)18 (30.0)Cell of origin n = 281 n = 244 n = 37GCB114 (40.6)101 (41.4)13 (35.1)ABC93 (33.1)78 (32.0)15 (40.5)Unclassified53 (18.9)45 (18.4)8 (21.6)Unknown21 (7.5)20 (8.2)1 (2.7)Double‐expressor lymphoma b n = 223 n = 197 n = 26Yes93 (41.7)84 (42.6)9 (34.6)Other130 (58.3)113 (57.4)17 (65.4)Double‐hit c n = 79 n = 68 n = 11Yes5 (6.3)3 (4.4)2 (18.2)Other74 (93.7)65 (95.6)9 (81.8)Abbreviations: ABC, activated B‐cell like; DLBCL, diffuse large B‐cell lymphoma; EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group; FAS, full analysis set; G8, Geriatric 8 survey; GCB, germinal center B‐cell like; IHC, immunohistochemistry; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MTX, methotrexate; NOS, not otherwise specified; ULN, upper limit of normal. a T‐cell/histocyte‐rich large B‐cell lymphoma, n = 2; primary mediastinal large B‐cell lymphoma, n = 1; MTX‐associated lymphoproliferative disorder, n = 1. b Patients with co‐expression of MYC and BCL2, as determined by IHC analysis, were regarded as double expressors; patients with unknown IHC results were excluded. c Double‐hit included patients positive for MYC and BCL2. Baseline demographic and clinical characteristics in the FAS. Abbreviations: ABC, activated B‐cell like; DLBCL, diffuse large B‐cell lymphoma; EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group; FAS, full analysis set; G8, Geriatric 8 survey; GCB, germinal center B‐cell like; IHC, immunohistochemistry; IPI, International Prognostic Index; LDH, lactate dehydrogenase; MTX, methotrexate; NOS, not otherwise specified; ULN, upper limit of normal. T‐cell/histocyte‐rich large B‐cell lymphoma, n = 2; primary mediastinal large B‐cell lymphoma, n = 1; MTX‐associated lymphoproliferative disorder, n = 1. Patients with co‐expression of MYC and BCL2, as determined by IHC analysis, were regarded as double expressors; patients with unknown IHC results were excluded. Double‐hit included patients positive for MYC and BCL2. Median time from initial diagnosis (defined as the date of biopsy) to treatment initiation was 26.0 days (range 4.0–428.0) in the FAS, and 26.0 days (range 4.0–428.0) and 23.5 days (range 9.0–211.0) in patients ≤ 80 years and > 80 years, respectively (Table 1). Planned treatment with Pola‐R‐CHP was completed by 419 (86.4%) patients in the FAS and by 46 (76.7%) patients > 80 years (Table S2). A total of 66 (13.6%) patients in the FAS discontinued treatment, 14 of whom were > 80 years. Reasons for treatment discontinuation are shown in Table S2. The median initial polatuzumab vedotin dose administered during Cycle 1 was 1.8 mg/kg (range 0.0–2.1) in the FAS and 1.8 mg/kg (range 1.0–1.9) for patients > 80 years (Table S3). Median RDIs in the FAS were 95.1% for rituximab, 93.2% for polatuzumab vedotin, 87.2% for cyclophosphamide, 87.5% for doxorubicin, and 89.7% for prednisolone (Table 2). Most patients > 80 years received reduced CHP doses from the first cycle; in this patient subgroup median RDIs were 95.8% for rituximab, 93.0% for polatuzumab vedotin, 51.6% for cyclophosphamide, 49.6% for doxorubicin, and 56.5% for prednisolone. A median of 6 treatment cycles of each drug was administered in the FAS and to patients > 80 years (See Table S4 for corresponding data for patients with low [0/1] vs. high [2–5] IPI). TABLE 2Relative dose intensity and number of cycles of treatment received in the FAS and among patients > 80 years.DrugFAS (N = 485)> 80 years (n = 60)Mean (SD)Median (range)Mean (SD)Median (range)RDI a (%)Rituximab92.3 (12.4)95.1 (0.0–125.4)92.8 (11.1)95.8 (44.3–107.5)Polatuzumab vedotin89.7 (12.7)93.2 (0.0–114.0)90.0 (12.7)93.0 (42.9–106.0)Cyclophosphamide80.4 (18.9)87.2 (7.4–103.7)54.4 (14.5)51.6 (7.4–86.8)Doxorubicin79.6 (20.3)87.5 (0.0–103.2)53.1 (14.6)49.6 (7.8–89.7)Prednisolone79.6 (21.9)89.7 (4.8–100.8)59.0 (22.1)56.5 (10.0–100.0)Number of cyclesRituximab6.4 (1.7)6.0 (0.0–8.0)6.2 (1.7)6.0 (1.0–8.0)Polatuzumab vedotin5.6 (1.2)6.0 (0.0–6.0)5.5 (1.2)6.0 (1.0–6.0)Cyclophosphamide5.6 (1.2)6.0 (1.0–8.0)5.4 (1.3)6.0 (1.0–6.0)Doxorubicin5.6 (1.2)6.0 (0.0–6.0)5.4 (1.3)6.0 (1.0–6.0)Prednisolone5.6 (1.2)6.0 (1.0–8.0)5.4 (1.3)6.0 (1.0–6.0)Abbreviations: FAS, full analysis set; RDI, relative dose intensity; SD, standard deviation. a The proportion of actual administered dose relative to planned dose. Relative dose intensity and number of cycles of treatment received in the FAS and among patients > 80 years. Abbreviations: FAS, full analysis set; RDI, relative dose intensity; SD, standard deviation. The proportion of actual administered dose relative to planned dose. Safety The incidence of Grade ≥ 3 AEs was 47.4% (n = 230) in the FAS and 56.7% (n = 34) in patients > 80 years (Table 3). In both the FAS and among patients > 80 years, the most frequently occurring Grade ≥ 3 AEs were hematologic events (neutrophil count decreased, white blood cell [WBC] count decreased, febrile neutropenia, and anemia) and lung infection. Compared with the overall FAS, patients > 80 years had a numerically higher incidence of Grade ≥ 3 febrile neutropenia (8.7% vs. 15.0%), anemia (5.2% vs. 8.3%), and lung infection (2.9% vs. 8.3%). Serious AEs occurred in 12.6% (n = 61) of patients in the FAS and were more common in patients > 80 years (25.0%; n = 15). Five deaths were reported in the FAS (pneumonitis, n = 2; COVID‐19 infection, n = 1; febrile neutropenia, n = 1; acute myeloid leukemia, n = 1), of which two (pneumonitis and febrile neutropenia) were reported in patients > 80 years (See Table S5 for safety in patients with low [0/1] vs. high [2–5] IPI). TABLE 3Safety overview in the FAS and among patients > 80 years. n (%)FAS (N = 485)> 80 years (n = 60)Common (≥ 5%) Grade ≥ 3 AEs230 (47.4)34 (56.7)Neutrophil count decreased124 (25.6)16 (26.7)White blood cell count decreased51 (10.5)5 (8.3)Febrile neutropenia42 (8.7)9 (15.0)Anemia25 (5.2)5 (8.3)Lung infection14 (2.9)5 (8.3)Serious AEs61 (12.6)15 (25.0)AEs leading to discontinuation of treatment with polatuzumab vedotin regardless of grade33 (6.8)9 (15.0)Death5 (1.0)2 (3.3)Infections and infestations, others (COVID‐19 infection)1 (0.2)0 (0)Pneumonitis2 (0.4)1 (1.7)Febrile neutropenia1 (0.2)1 (1.7)Neoplasms benign, malignant and unspecified (including cysts and polyps), Others (acute myeloid leukemia)1 (0.2)0 (0)Abbreviations: AE, adverse event; FAS, full analysis set. Safety overview in the FAS and among patients > 80 years. Abbreviations: AE, adverse event; FAS, full analysis set. Thirty‐three (6.8%) patients in the FAS discontinued treatment with polatuzumab vedotin due to AEs related to any component of Pola‐R‐CHP of which 9 patients (15.0%) were > 80 years (Tables 3 and 4). The most common AEs leading to polatuzumab vedotin discontinuation were COVID‐19 infection, peripheral sensory neuropathy, and heart failure (n = 4, 0.8% each) in the FAS, and pneumonitis (n = 2, 3.3%) in patients > 80 years (See Table S6 for discontinuation of polatuzumab vedotin due to AEs in patients with low [0/1] vs. high [2–5] IPI). TABLE 4AEs leading to polatuzumab vedotin discontinuation in the FAS and among patients > 80 years. n (%)FAS (N = 485)Age > 80 years (n = 60)All gradesGrade ≥ 3All gradesGrade ≥ 3All events33 (6.8)26 (5.4)9 (15.0)6 (10.0)Fibrinogen decreased1 (0.2)1 (0.2)00Infections and infestations, others:COVID‐19 infection4 (0.8)3 (0.6)1 (1.7)1 (1.7)Enterocolitis pseudomembranous1 (0.2)1 (0.2)1 (1.7)1 (1.7)Malaise1 (0.2)1 (0.2)00Hip fracture1 (0.2)1 (0.2)1 (1.7)1 (1.7)Neutrophil count decreased1 (0.2)1 (0.2)00Small intestinal perforation1 (0.2)1 (0.2)00Anorexia2 (0.4)2 (0.4)1 (1.7)1 (1.7)Pericardial effusion1 (0.2)1 (0.2)00Heart failure4 (0.8)2 (0.4)1 (1.7)0Weight gain1 (0.2)1 (0.2)00Stroke1 (0.2)1 (0.2)00Lung infection3 (0.6)2 (0.4)1 (1.7)0 (0.0)Pneumonitis3 (0.6)3 (0.6)2 (3.3)2 (3.3)Febrile neutropenia1 (0.2)1 (0.2)1 (1.7)1 (1.7)Constipation1 (0.2)1 (0.2)00Gait disturbance1 (0.2)1 (0.2)00Peripheral sensory neuropathy4 (0.8)1 (0.2)1 (1.7)0Neoplasms benign, malignant and unspecified (including cysts and polyps), others2 (0.4) a 2 (0.4) a 00Abbreviations: AE, adverse event; FAS, full analysis set. a Includes n = 1 each of acute myeloid leukemia and cholangiocarcinoma. AEs leading to polatuzumab vedotin discontinuation in the FAS and among patients > 80 years. Abbreviations: AE, adverse event; FAS, full analysis set. Includes n = 1 each of acute myeloid leukemia and cholangiocarcinoma. Forty‐two patients experienced febrile neutropenia with most occurring in Cycle 1 (FAS: 23/42 [54.8%]; > 80 years: 4/9 [44.4%]). There was no difference in the frequency of administration of granulocyte‐colony stimulating factor in the FAS and among patients > 80 years (Figure 1). Frequency of G‐CSF administration in the (A) FAS and (B) patients > 80 years. Abbreviations: FAS, full analysis set; G‐CSF, granulocyte‐colony stimulating factor. When patients in the FAS were stratified by age (< 65 years vs. ≥ 65 years), the incidence of any Grade ≥ 3 AEs was 14.8% higher in those ≥ 65 years (Table S7). In patients ≥ 65 years who completed the G8 survey (n = 330), those with a G8 score of ≤ 14 had a 10.3% higher incidence of Grade ≥ 3 AEs, including a higher incidence of Grade ≥ 3 febrile neutropenia (12.8% vs. 3.4%) and anemia (7.4% vs. 3.4%), than those with a G8 score of > 14. Median time from start of treatment to first occurrence of all Grade ≥ 3 AEs reported in ≥ 5% of the FAS was 13.0 days (range 1.0–240.0) and was slightly longer in patients > 80 years (15.0 days [range 1.0–166.0]; Table S8). Most Grade ≥ 3 AEs occurred during Cycle 1 and generally resolved within a median of approximately one week or less in the FAS and approximately 1–2 weeks in patients > 80 years. Response to Treatment In the efficacy‐evaluable population (n = 444; of which n = 392 [88.3%] patients were assessed using PET/CT), EOT response rates were 93.2% (95% CI: 90.5–95.2) for ORR and 83.3% (95% CI: 79.6–86.5) for CRR (Figure 2). Overall, 78.6% (n = 349) of evaluable patients achieved a complete response (CR), 9.9% (n = 44) achieved a partial response (PR), and 1.1% (n = 5) achieved stable disease. Twenty‐four patients (5.4%) had progressive/relapsing disease. ORR and CRR were also consistent regardless of age, COO subtype, and IPI status (Figure 2). Investigator assessed EOT response assessments. aResponse was assessed at completion or discontinuation of treatment in patients with baseline data (efficacy‐evaluable population). Abbreviations: ABC, activated B‐cell; CI, confidence interval; COO, cell of origin; CR, complete response; CRR, complete response rate (CR + CRu); CRu, complete response unconfirmed; EOT, end‐of‐treatment; FAS, full analysis set; GCB, germinal center B‐cell; IPI, International Prognostic Index; NE, not evaluable; ORR, overall response rate (CR + CRu + PR); PD, progressive disease; PR, partial response; RD, relapsing disease; SD, stable disease. Discussion In this pre‐specified interim analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, the safety and efficacy of Pola‐R‐CHP were consistent with previously reported primary findings of the Phase III POLARIX study, with no new safety signals identified [5]. Patients in this study had a median age of 71.0 years, which was older than patients in the Pola‐R‐CHP arm of the POLARIX population (median 65 years) [5], and 12.4% (n = 60) of patients were > 80 years. The current study also included patients with low IPI scores (0/1, 26.3%), compared with POLARIX that only included patients with IPI scores of 2–5 [5]. Hematological toxicities and lung infection were the most common Grade ≥ 3 AEs reported with Pola‐R‐CHP, and COVID‐19 infection (n = 4), peripheral sensory neuropathy (n = 4), heart failure (n = 4), lung infection (n = 3), and pneumonitis (n = 3) were the most common AEs leading to discontinuation of polatuzumab vedotin. Compared with the FAS, patients > 80 years had an approximately 10% higher incidence of Grade ≥ 3 AEs and AEs leading to discontinuation of polatuzumab vedotin, and a higher incidence of Grade ≥ 3 febrile neutropenia (15.0% vs. 8.7%), anemia (8.3% vs. 5.2%), and lung infection (8.3% vs. 2.9%). Similarly, patients ≥ 65 years with a lower G8 score indicative of frailty (≤ 14 vs. > 14 [non‐frail]) had an approximately 10% higher incidence of Grade ≥ 3 AEs. This included a higher incidence of Grade ≥ 3 febrile neutropenia (12.8% vs. 3.4%) and anemia (7.4% vs. 3.4%) among patients ≥ 65 years with a G8 ≤ 14 (vs G8 > 14). Overall, patients with a G8 score ≤ 14 had a higher incidence of AEs compared with patients with a G8 score of > 14, and should be monitored and managed carefully. ORR (93%) and CRR (83%) at EOT were high and consistent among the overall population, in patients > 80 years (87%/80%), and regardless of IPI status (IPI 0/1: 96%/92%; IPI 2–5: 93%/80%), and COO subtypes (GCB: 95%/84%; ABC: 97%/89%; unclassified: 90%/79%). Of note, in patients > 80 years, the initial doses of chemotherapy administered were approximately half that administered to patients in the FAS, and the median RDI of the chemotherapy components (CHP) was also reduced (50%–57% vs. 87%–90% for the FAS). In contrast, the initial doses of polatuzumab vedotin and rituximab administered to the FAS and patients > 80 years were comparable as were the median RDIs (polatuzumab vedotin both ~93%; rituximab both ~95%). However, the high response rates in patients > 80 years were comparable to the FAS suggesting that chemotherapy dose reduction for frontline Pola‐R‐CHP is not associated with reduced efficacy and is a feasible option when treating elderly patients with DLBCL. A strength of POLASTAR is the inclusion of patients who were ineligible for POLARIX (e.g., those > 80 years), with appropriate dose reductions implemented. This allowed enrollment of a diverse patient cohort that is more representative of real‐world clinical practice compared with clinical trials. To our knowledge, POLASTAR is the first large prospective observational study conducted to date, underscoring its value in providing robust real‐world evidence to complement findings from clinical trials. Results from several prior studies also suggest that patients with newly diagnosed DLBCL, including the elderly, can benefit from treatment with Pola‐R‐CHP [15, 16, 17]. In a post hoc subgroup analysis of POLARIX in patients ≥ 60 years (n = 629), Pola‐R‐CHP improved PFS versus R‐CHOP, most notably among patients ≥ 70 years who had a 37% reduction in risk of disease progression, relapse or death (unstratified hazard ratio, 0.63 [95% CI: 0.41–0.96]) [15]. Pola‐R‐CHP also had a generally similar safety profile versus R‐CHOP, including similar rates of Grade 3/4 AEs (62.7% vs. 61.5%), Grade 3–5 infections (15.0% vs. 12.9%), and Grade 5 AEs (3.6% vs. 3.2%) but a higher rate of Grade 3/4 febrile neutropenia (16.3% vs. 7.6%) [15]. Alternative studies have explored the efficacy and safety of reduced dose Pola‐R‐CHP regimens in elderly patients with newly diagnosed DLBCL [16, 17]. Initial safety findings from the Phase III POLAR BEAR study in Europe (n = 127 patients, either > 80 years or 75–80 years and frail, were included) reported a similar incidence of Grade 2/3 hematological AEs, infection risk and neuropathy but a higher risk of gastrointestinal AEs with a Pola‐R‐CHP regimen comprising attenuated chemotherapy doses (Pola‐R‐mini‐CHP) versus R‐mini‐CHOP [16]. In a real‐world study in Japanese patients > 80 years (n = 38) treated with reduced‐dose Pola‐R‐CHP, 12‐month PFS was comparable with that observed in POLARIX (78.5% vs. POLARIX 76.7%) [5, 17]. However, 12‐month OS was significantly higher among patients who maintained an average chemotherapy RDI ≥ 70% (vs < 70%: 100% vs. 75%; p = 0.015), highlighting the importance of maintaining the highest RDI possible to preserve treatment efficacy [17]. In our study, a longer follow‐up period is required to clarify the correlation between RDI and treatment efficacy. Our interim analysis had limitations. Firstly, the follow‐up period was relatively short (last patient in: 6 December 2023; data cut‐off: 31 August 2024), although most patients (99.8%) completed the safety evaluation period. Secondly, as only Grade ≥ 3 AEs and any‐grade AEs leading to polatuzumab vedotin discontinuation were collected, the safety profile did not capture the full spectrum of treatment‐emergent AEs with Pola‐R‐CHP. As a result, the full spectrum of treatment‐emergent peripheral neuropathy (PN) events, particularly lower‐grade events, may not have been fully represented. Nonetheless, our results indicate that Pola‐R‐CHP has a favorable PN profile, with few high‐grade events and minimal treatment discontinuations. This is consistent with POLARIX, where most PN events were grade 1/2 and only 1% of patients required polatuzumab vedotin/vincristine discontinuation [18]. Thirdly, efficacy was not centrally assessed; as a prospective observational study, the timing and modality of response evaluation were determined by each investigator. Finally, as POLASTAR enrolled only patients receiving Pola‐R‐CHP, no comparison can be made with other regimens such as R‐CHOP, especially in patient subgroups not eligible for POLARIX (e.g., IPI 0/1 or > 80 years). In conclusion, Pola‐R‐CHP demonstrated effectiveness in a real‐world setting across a broad range of patients, including the elderly, when administered with appropriate safety monitoring and dose modifications. Patient follow‐up is ongoing, and additional analyses will be reported in the future. Author Contributions Takahiro Kumode: conceptualization, methodology, data curation, resources, writing – original draft, writing – review and editing, formal analysis. Hitomi Sawa: resources, data curation, formal analysis, writing – original draft, writing – review and editing. Kohta Miyawaki: resources, formal analysis, writing – original draft, writing – review and editing. Atsushi Satake: resources, formal analysis, writing – original draft, writing – review and editing. Nobuhiro Kanemura: resources, formal analysis, writing – original draft, writing – review and editing. Ritsuro Suzuki: resources, formal analysis, writing – original draft, writing – review and editing. Yuki Fujiwara: formal analysis, resources, writing – review and editing, writing – original draft. Yasuhiro Nagate: formal analysis, resources, writing – original draft, writing – review and editing. Shuichi Ota: resources, formal analysis, writing – original draft, writing – review and editing. Takahiro Fujino: resources, formal analysis, writing – original draft, writing – review and editing. Hideki Goto: conceptualization, methodology, writing – original draft, writing – review and editing. Noriko Fukuhara: conceptualization, methodology, data curation, resources, writing – review and editing, writing – original draft. Mamiko Sakata‐Yanagimoto: conceptualization, methodology, resources, data curation, writing – original draft, writing – review and editing. Koji Izutsu: conceptualization, methodology, writing – original draft, writing – review and editing. Momoko Nishikori: conceptualization, methodology, writing – original draft, writing – review and editing. Hirohiko Shibayama: conceptualization, methodology, resources, data curation, writing – original draft, writing – review and editing. Daisuke Ennishi: conceptualization, methodology, writing – original draft, writing – review and editing. Takayuki Shimose: writing – original draft, writing – review and editing. Mai Asai: writing – original draft, writing – review and editing. Itaru Matsumura: resources, data curation, writing – original draft, writing – review and editing. Koichi Akashi: writing – original draft, writing – review and editing, resources, data curation. Koji Kato: conceptualization, methodology, data curation, resources, writing – original draft, writing – review and editing. Funding This study was funded by Chugai Pharmaceutical Co. Ltd. Ethics Statement This study was conducted in compliance with the Declaration of Helsinki, the Act on the Protection of Personal Information, and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. Patients were able to withdraw from the study at any time. The study protocol was reviewed and approved by the centralized ethics committee (Clinical Research Network Fukuoka Certified Review Board). Consent All patients provided written informed consent for participation in the study. Conflicts of Interest Takahiro Kumode: AbbVie, AstraZeneca, BeiGene, Chugai Pharmaceutical Co. Ltd., Genmab, Janssen Pharmaceutical, Ono Pharmaceuticals (speaker's bureau). Hitomi Sawa: Janssen Pharmaceutical K.K. (honoraria). Kohta Miyawaki: BMS, Chugai Pharmaceutical Co., Genmab, Novartis, SymBio Pharmaceuticals (honoraria). Atsushi Satake: Chugai Pharmaceutical Co. Ltd. (honoraria). Nobuhiro Kanemura: Chugai Pharmaceutical Co. Ltd. (honoraria). Ritsuro Suzuki: Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Kyowa Kirin Shionogi, Taiho, Otsuka (research funding); AbbVie, AstraZeneca, BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Janssen, Kyowa Kirin, Meiji‐Seika, MSD, Novartis, Otsuka, Takeda Pharmaceutical (honoraria); Cancer Science (editorial board member). Yuki Fujiwara: no conflicts of interest. Yasuhiro Nagate: Amgen, Chugai Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Ono Pharmaceuticals, Symbio Pharmaceuticals Ltd. (speaker's bureau). Shuichi Ota: AbbVie, Amgen, AstraZeneca, BMS, Janssen, Novartis, PharmaEssentia, Sanofi, Takeda Pharmaceutical (honoraria). Takahiro Fujino: Chugai Pharmaceutical Co. Ltd., Johnson & Johnson, Nippon Shinyaku Co. Ltd. (honoraria); AbbVie, Chugai Pharmaceutical Co. Ltd., Johnson & Johnson, Kyowa Kirin, Nippon Shinyaku Co. Ltd. (speaker's bureau). Hideki Goto: AbbVie, BMS, Kyowa Kirin, Sanofi (research funding); AbbVie, BMS, Chugai Pharmaceutical Co. Ltd., Gilead, Kyowa Kirin, MSD, Novartis, Takeda Pharmaceutical (honoraria). Noriko Fukuhara: AbbVie, Chugai Pharmaceutical Co. Ltd., Chordia Therapeutics, Genmab, Incyte, Kyowa Kirin, Loxo Oncology, Takeda Pharmaceutical (research funding); AstraZeneca, BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Eli Lilly, Genmab, Gilead, Janssen, Meiji Seika Pharma, Nihon Kayaku, Novartis, Ono Pharmaceuticals, Soreisia, Symbio, Takeda Pharmaceutical (honoraria). Mamiko Sakata‐Yanagimoto: BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd. (research funding); LSI Medicine (patents and royalties); AbbVie, Astellas, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Janssen, Kyowa Kirin, Meiji Seika, MSD, Nippon Kayaku, Nippon Shinyaku, Takeda Pharmaceutical (speaker's bureau); Cancer Science (editorial board member). Koji Izutsu: AbbVie, AstraZeneca, BeiGene, BMS, Carna Biosciences, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Ono Pharmaceuticals, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD, Nihon Shinyaku, Novartis, Otsuka, Takeda Pharmaceutical, Yakult, Zenyaku (consultancy); AbbVie, AstraZeneca, Bayer, BeiGene, BMS, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo, Genmab, Gilead, Incyte, Janssen, Kyowa Kirin, Loxo Oncology, MSD, Novartis, Otsuka, Pfizer, Regeneron, Yakult (research funding); AbbVie, Astellas, AstraZeneca, BMS, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo, Eisai Pharmaceutical Co. Ltd., Eli Lilly, Genmab, Gilead, Janssen, Kyowa Kirin, Meiji Seika Pharma, MSD, Nihon Kayaku, Novartis, Ono Pharmaceuticals, Otsuka, Pfizer, Symbio, Takeda Pharmaceutical (honoraria). Momoko Nishikori: SymBio Pharmaceuticals (research funding); AbbVie, AstraZeneca, BMS, Chugai Pharmaceutical Co. Ltd., Genmab, Janssen Pharma, Kyowa Kirin, Nippon Shinyaku, Ono Pharmaceuticals, Ohara Pharmaceutical, Otsuka, Sumitomo Pharma, SymBio, Takeda Pharmaceutical (honoraria). Hirohiko Shibayama: AstraZeneca, Chugai Pharmaceutical Co. Ltd., Fujimoto, Janssen, Meiji Seika Pharma, Nippon Shinyaku, Ono Pharmaceuticals (honoraria); Chugai Pharmaceutical Co. Ltd., (advisory); Novartis, Ono (research funding). Daisuke Ennishi: Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Nippon Shinyaku Pharmaceutical Co. Ltd. (research funding); BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Kyowa Kirin, Nippon Shinyaku Pharmaceutical Co. Ltd., Ono Pharmaceuticals, SymBio Pharmaceuticals Co. Ltd. (honoraria). Takayuki Shimose: no conflicts of interest. Mai Asai: Chugai Pharmaceutical Co. Ltd. (current employment); Chugai Pharmaceutical Co. Ltd. (stock or stock options). Itaru Matsumura: Otsuka Pharmaceutical (consultancy); AbbVie GK, Asahi Kasei Pharma, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Genmab, Incyte Japan, Kyowa Kirin, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, Sumitomo Pharma, Taiho (research funding); AbbVie, Astellas Pharma, AstraZeneca, BMS, Chugai Pharmaceutical Co. Ltd., Janssen Pharmaceutical, Novartis Pharma, Ono Pharmaceuticals, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, SymBio Pharmaceuticals, Takeda Pharmaceutical (speaker's bureau). Koichi Akashi: AbbVie, Asahi Kasei Pharma, Chugai Pharmaceutical Co. Ltd., Kyowa Kirin, Otsuka, Taiho (research funding); AbbVie, Asahi Kasei Pharma, Astellas, AstraZeneca, BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Janssen, Kyowa Kirin (honoraria). Koji Kato: Astellas, AbbVie, BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Genmab, Gilead Sciences, Janssen, Japan Blood Products Organization, Kyowa Kirin, LSI Medience, Meiji, MSD, Nippon Shinyaku, Novartis, Ono Pharmaceuticals, Takeda Pharmaceutical (research funding); AbbVie, Astellas, BMS, Chugai Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Genmab, Gilead Sciences, Janssen, Japan Blood Products Organization, Kyowa Kirin, MSD, Meiji, Nippon Shinyaku, Novartis, Otsuka (honoraria). Supporting information Table S1: Baseline demographic and clinical characteristics in patients with a low IPI (0/1) versus high IPI (2–5). Table S2: Treatment completion and reasons for treatment discontinuation. Table S3: Initial doses administered in the FAS, and to patients ≤ 80 and > 80 years. Table S4: Relative dose intensity and number of cycles of treatment received in patients with a low IPI (0/1) versus high IPI (2–5). Table S5: Safety overview in patients with a low IPI (0/1) versus high IPI (2–5). Table S6: AEs leading to polatuzumab vedotin discontinuation in patients with a low IPI (0/1) versus high IPI (2–5). Table S7: Grade ≥ 3 AEs in patients aged < 65 versus ≥ 65 years, and those aged ≥ 65 years with G8 survey results (G8 score > 14 vs. ≤ 14). Table S8: Time from start of treatment to initial onset and resolution of Grade ≥ 3 AEs (reported in ≥ 5% of patients) in the FAS and among patients aged ≤ 80 years and > 80 years.